Sharing new clinical evidence from three clinical studies, Hoya Vision Care said wearing Miyosmart spectacle lenses continuously and for the long-term may improve myopia management outcomes.
Presenting findings from Hoya’s eight-year clinical study on myopia management spectacle lenses at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting earlier this year, it found continuous Defocus Incorporated Multiple Segments (DIMS) technology spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D) and axial elongation (0.42 ±0.18mm) consistently for the full eight years (n=11) of follow-up.
The first 12-month data from the ASPECT (Atropine and Spectacle lens Combination Treatment) randomised controlled trial showed that combining low-dose atropine eye drops (0.025%) with DIMS spectacle lenses stopped myopia progression in close to 40% of children. The mean change in axial length was significantly lower than in the atropine-only group (0.07 ± 0.16mm vs 0.18 ± 0.16mm). Exploring vision-related quality of life, the researchers noted a trend towards improvement in general vision and competence in children using low-dose atropine and DIMS spectacle lens combination treatment.
Lastly, a first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in five- and six-year-old children indicated the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48mm to 22.64mm), the choroidal thickness remained stable.
“These promising initial findings suggest Miyosmart spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research,” Hoya said.
